[Special Stock] Shaperon Continues New Drug Development Success... Rising Value with Entry into Anti-Inflammatory Market

Shaperon is showing strong performance. Recently, visible achievements in new drug development appear to be influencing its stock price. News that preclinical results of next-generation anticancer immunotherapy technology targeting cancer stem cells were published in an international professional journal seems to be affecting the stock price.

As of 9:42 AM on the 18th, Shaperon was trading at 2,610 KRW, up 310 KRW (13.48%) compared to the previous trading day.

Shaperon, a bio company specializing in innovative immuno-oncology drug development, announced that it published excellent preclinical results of next-generation anticancer immunotherapy technology targeting cancer stem cells in the international professional journal Biomedicine & Pharmacotherapy (Impact Factor (IF) 7.5). This anticancer immunotherapy technology is being jointly developed by Shaperon and researchers from Seoul National University College of Medicine.

Shaperon is accelerating new drug development by expanding and completing beta testing of the screening algorithm of its artificial intelligence (AI) drug development platform, 'Aiden.' The screening algorithm is a technology that predicts the efficacy, toxicity, and pharmacokinetics of substances in the body to discover candidate compounds.

Shaperon plans to further expand Aiden’s screening algorithm to conduct research on various inflammasomes, including the ‘NLRP3’ inflammasome currently under study. The company expects that developing optimized drugs acting on various types of inflammasomes will enable effective treatment.

According to industry sources, the global anti-inflammatory drug market reached approximately $120.4 billion in 2023 and is expected to grow to over $272.3 billion by 2033. Even securing just 1% market share in the anti-inflammatory drug market is projected to generate annual sales of $1.3 billion (approximately 1.8 trillion KRW).

It is also known that Shaperon is developing an oral obesity treatment candidate. NuBesin® has completed animal testing and entered the preclinical stage. The developed formulation is oral, and the preclinical stage appears to be aimed at developing an ‘oral obesity treatment.’ NuBesin is presumed to treat obesity by targeting the immune protein ‘inflammasome,’ which activates inflammatory responses, thereby regulating inflammation.